SkinBioTherapeutics PLC Cash Flow-to-Debt Ratio
SkinBioTherapeutics PLC cash flow-to-debt ratio. SkinBioTherapeutics PLC (SBTX) has a Cash Flow-to-Debt Ratio of -0.18x as of June 2025, meaning its operating cash flow of GBX-494.84K could theoretically repay 0% of its total liabilities (GBX2.71 Million) in one year. Check SBTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SkinBioTherapeutics PLC (2016–2025)
Cash flow-to-debt ratio of SkinBioTherapeutics PLC from 2016 to 2025. Historical debt coverage capacity for SkinBioTherapeutics PLC across 10 annual periods. Also explore SkinBioTherapeutics PLC annual equity growth to track the company's year-over-year net asset growth rate.
SkinBioTherapeutics PLC Cash Flow-to-Debt Ratio by Year (2016–2025)
SkinBioTherapeutics PLC cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for SkinBioTherapeutics PLC. For the full cash flow conversion analysis, see SkinBioTherapeutics PLC (SBTX) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.30 Million | GBX2.71 Million | ▲ +60.5% |
| 2024 | -1.21x | GBX-2.73 Million | GBX2.25 Million | ▲ +72.5% |
| 2023 | -4.41x | GBX-2.65 Million | GBX599.34K | ▼ -0.7% |
| 2022 | -4.38x | GBX-2.67 Million | GBX609.61K | ▼ -46.5% |
| 2021 | -2.99x | GBX-1.56 Million | GBX519.67K | ▼ -2.2% |
| 2020 | -2.93x | GBX-892.14K | GBX304.83K | ▲ +75.1% |
| 2019 | -11.77x | GBX-1.43 Million | GBX121.33K | ▼ -269.0% |
| 2018 | -3.19x | GBX-667.75K | GBX209.29K | ▲ +37.9% |
| 2017 | -5.14x | GBX-609.70K | GBX118.66K | ▼ -14711.9% |
| 2016 | -0.03x | GBX-1.17K | GBX33.64K | — |